Develo raises $14M led by Blueprint Equity to expand its AI-native pediatric operating system. Discover how it unifies ...

Health care tech company Veradigm said yesterday it could not find a buyer during a review of strategic alternatives and it is now conducting another review to find ways to improve its organization ...

Buy MDRX slightly over 11.66 target 13.72 stop loss @ 11.63 Details The technical summary data tells us to buy MDRX near 11.66 with an upside target of 13.72. This data also tells us to set a stop ...

The “US Digital Health Market (by Technology & Component): Insights & Forecast with Potential Impact of COVID-19 (2023-2027)” report has been added to ResearchAndMarkets.com’s offering. The U.S.

UPDATE: Sept. 25, 2023: Veradigm has received notice that its shares will be delisted from the Nasdaq after the health IT company failed to file required financial paperwork before the end of the ...

Greetings, and welcome to Allscripts' Third Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference ...

In its third-quarter 2022 earnings report posted Nov. 3, revenues for Veradigm, Allscripts’ life sciences and payer business, were $145 million compared with $137 million in the previous third quarter ...

The market expects AllScripts Healthcare (MDRX) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2022. This widely-known ...